SignaCor Therapeutics
Clinical-stage drug development company advancing treatments for hypertrophic cardiomyopathy and cardiovascular health.
About
No comments yet. Be the first to share your take.
What does SignaCor Therapeutics do?
SignaCor Therapeutics is a clinical-stage drug development company spun out from Queen's University Belfast. They are developing first-in-class therapies for symptomatic hypertrophic cardiomyopathy (HCM) that target underlying disease pathology to reverse heart damage and improve patient outcomes.
How much funding has SignaCor Therapeutics raised?
SignaCor Therapeutics has raised a total of $315K in funding. The most recent round on record is Seed.
Where is SignaCor Therapeutics headquartered?
SignaCor Therapeutics is headquartered in Belfast, United Kingdom.
When was SignaCor Therapeutics founded?
SignaCor Therapeutics was founded in 2024.
What industry does SignaCor Therapeutics operate in?
SignaCor Therapeutics operates in HealthTech, Biotechnology, Cardiovascular Health, Cardiovascular.